168 related articles for article (PubMed ID: 37649020)
1. CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma.
Li H; Song W; Wu J; Shi Z; Gao Y; Li J; Han L; Zhang J; Li Z; Li Y; Zhang M
BMC Med; 2023 Aug; 21(1):330. PubMed ID: 37649020
[TBL] [Abstract][Full Text] [Related]
2. A second-generation CD38-CAR-T cell for the treatment of multiple myeloma.
Li H; Li J; Wu J; Shi Z; Gao Y; Song W; Li J; Li Z; Zhang M
Cancer Med; 2023 May; 12(9):10804-10815. PubMed ID: 37039305
[TBL] [Abstract][Full Text] [Related]
3. [Functional investigation of chimeric antigen receptor T cells targeting LMP1 antigen].
He HZ; Xing YY; Zhang Y; Xu YX; Tian Z; Xing HY; Tang KJ; Rao Q; Wang JX; Wang M
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):229-234. PubMed ID: 35405781
[No Abstract] [Full Text] [Related]
4. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the Power of CAR-NK Cells: A Promising Off-the-Shelf Therapeutic Strategy for CD38-Positive Malignancies.
Asadi M; Kiani R; Razban V; Faraji SN; Ahmadi A; Fallahi J; Ramezani A; Erfani N
Iran J Immunol; 2023 Dec; 20(4):410-426. PubMed ID: 38102941
[TBL] [Abstract][Full Text] [Related]
6. Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.
Karvouni M; Vidal-Manrique M; Susek KH; Hussain A; Gilljam M; Zhang Y; Gray JD; Lund J; Kaufmann G; Ljunggren HG; Ji H; Lundqvist A; Wagner AK; Guo W; Alici E
Cytotherapy; 2023 Jul; 25(7):763-772. PubMed ID: 37055320
[TBL] [Abstract][Full Text] [Related]
7. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
8. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
9. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
10. Expanding anti-CD38 immunotherapy for lymphoid malignancies.
Wang X; Yu X; Li W; Neeli P; Liu M; Li L; Zhang M; Fang X; Young KH; Li Y
J Exp Clin Cancer Res; 2022 Jun; 41(1):210. PubMed ID: 35765110
[TBL] [Abstract][Full Text] [Related]
11. Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.
An N; Hou YN; Zhang QX; Li T; Zhang QL; Fang C; Chen H; Lee HC; Zhao YJ; Du X
Mol Pharm; 2018 Oct; 15(10):4577-4588. PubMed ID: 30185037
[TBL] [Abstract][Full Text] [Related]
12. Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells.
Edri A; Ben-Haim N; Hailu A; Brycman N; Berhani-Zipori O; Rifman J; Cohen S; Yackoubov D; Rosenberg M; Simantov R; Teru H; Kurata K; Anderson KC; Hendel A; Pato A; Geffen Y
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139060
[TBL] [Abstract][Full Text] [Related]
13. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
[TBL] [Abstract][Full Text] [Related]
14. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
15. CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells.
Liao C; Wang Y; Huang Y; Duan Y; Liang Y; Chen J; Jiang J; Shang K; Zhou C; Gu Y; Liu N; Zeng X; Gao X; Tang Y; Sun J
Adv Sci (Weinh); 2023 Sep; 10(27):e2207394. PubMed ID: 37485647
[TBL] [Abstract][Full Text] [Related]
16. Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma.
Feng Y; Liu X; Li X; Zhou Y; Song Z; Zhang J; Shi B; Wang J
Oncoimmunology; 2021; 10(1):1959102. PubMed ID: 34434610
[TBL] [Abstract][Full Text] [Related]
17. Single-Cell Analysis Reveals Malignant Cells Reshape the Cellular Landscape and Foster an Immunosuppressive Microenvironment of Extranodal NK/T-Cell Lymphoma.
Li YQ; Luo CL; Jiang JX; He S; Liu Y; Yan WX; Xia Y; Cui Q; Huang Y; Lim JQ; Huang D; Hussein IN; Gao Y; Lin GW; Ling YH; Ma D; Zhang YT; Chan JY; Wei PP; Wang XX; Cheng CL; Xiong J; Zhao WL; Ong CK; Lim ST; Huang HQ; Peng RJ; Bei JX
Adv Sci (Weinh); 2023 Dec; 10(36):e2303913. PubMed ID: 37949673
[TBL] [Abstract][Full Text] [Related]
18. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
[TBL] [Abstract][Full Text] [Related]
19. Updating targets for natural killer/T-cell lymphoma immunotherapy.
Xue W; Zhang M
Cancer Biol Med; 2021 Feb; 18(1):52-62. PubMed ID: 33628584
[TBL] [Abstract][Full Text] [Related]
20. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]